ITRM20050389A1 - Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. - Google Patents

Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.

Info

Publication number
ITRM20050389A1
ITRM20050389A1 IT000389A ITRM20050389A ITRM20050389A1 IT RM20050389 A1 ITRM20050389 A1 IT RM20050389A1 IT 000389 A IT000389 A IT 000389A IT RM20050389 A ITRM20050389 A IT RM20050389A IT RM20050389 A1 ITRM20050389 A1 IT RM20050389A1
Authority
IT
Italy
Prior art keywords
receptors
egf
compounds
medical fields
specific salts
Prior art date
Application number
IT000389A
Other languages
English (en)
Italian (it)
Inventor
Sergio Baroni
Giancarlo Naccari
Original Assignee
Giuliani Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37579831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITRM20050389(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Giuliani Spa filed Critical Giuliani Spa
Priority to IT000389A priority Critical patent/ITRM20050389A1/it
Priority to BRPI0613396-7A priority patent/BRPI0613396B1/pt
Priority to EP06766085.2A priority patent/EP1910270B3/en
Priority to NZ592228A priority patent/NZ592228A/xx
Priority to US11/989,090 priority patent/US8153841B2/en
Priority to CN2006800300777A priority patent/CN101243039B/zh
Priority to CN2010105208008A priority patent/CN102020577B/zh
Priority to PL06766085T priority patent/PL1910270T6/pl
Priority to PT67660852T priority patent/PT1910270E/pt
Priority to SI200631598T priority patent/SI1910270T1/sl
Priority to EA201000708A priority patent/EA017566B1/ru
Priority to HRP20130549TT priority patent/HRP20130549T4/hr
Priority to PCT/IE2006/000078 priority patent/WO2007010516A2/en
Priority to UAA200802141A priority patent/UA100359C2/uk
Priority to NZ566045A priority patent/NZ566045A/en
Priority to MX2013012753A priority patent/MX366596B/es
Priority to DK06766085.2T priority patent/DK1910270T6/en
Priority to EA200800372A priority patent/EA014665B3/ru
Priority to JP2008522170A priority patent/JP5312026B2/ja
Priority to KR1020087003953A priority patent/KR101317519B1/ko
Priority to ES06766085.2T priority patent/ES2421260T7/es
Priority to AU2006271165A priority patent/AU2006271165C1/en
Priority to CA2616146A priority patent/CA2616146C/en
Publication of ITRM20050389A1 publication Critical patent/ITRM20050389A1/it
Priority to IL188878A priority patent/IL188878A/en
Priority to NO20080325A priority patent/NO340680B1/no
Priority to ZA2008/01671A priority patent/ZA200801671B/en
Priority to IL205992A priority patent/IL205992A/en
Priority to ZA2010/08268A priority patent/ZA201008268B/en
Priority to US13/408,439 priority patent/US8710100B2/en
Priority to CY20131100562T priority patent/CY1114294T1/el
Priority to US14/202,386 priority patent/US9133099B2/en
Priority to US14/671,579 priority patent/US9561202B2/en
Priority to US14/671,585 priority patent/US9345680B2/en
Priority to US15/377,013 priority patent/US10016381B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
IT000389A 2005-07-22 2005-07-22 Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. ITRM20050389A1 (it)

Priority Applications (34)

Application Number Priority Date Filing Date Title
IT000389A ITRM20050389A1 (it) 2005-07-22 2005-07-22 Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
CA2616146A CA2616146C (en) 2005-07-22 2006-07-24 Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field
DK06766085.2T DK1910270T6 (en) 2005-07-22 2006-07-24 For PPAR receptors and EGF receptors specific compounds and their salts as well as their application in the medical field
EA200800372A EA014665B3 (ru) 2005-07-22 2006-07-24 Соединения и их соли, специфичные к ppar рецепторам и egf рецепторам, и их применение в области медицины
NZ592228A NZ592228A (en) 2005-07-22 2006-07-24 Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
US11/989,090 US8153841B2 (en) 2005-07-22 2006-07-24 Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
CN2006800300777A CN101243039B (zh) 2005-07-22 2006-07-24 Ppar受体和egf受体特异性化合物及其盐以及它们在医药领域中的用途
CN2010105208008A CN102020577B (zh) 2005-07-22 2006-07-24 Ppar受体和egf受体特异性化合物及其盐以及它们在医药领域中的用途
PL06766085T PL1910270T6 (pl) 2005-07-22 2006-07-24 Związki i ich sole swoiste dla receptorów PPAR i receptorów EGF oraz ich zastosowanie w medycynie
PT67660852T PT1910270E (pt) 2005-07-22 2006-07-24 Compostos e seus sais específicos para os receptores ppar e os receptores de egf e sua utilização no campo médico
SI200631598T SI1910270T1 (sl) 2005-07-22 2006-07-24 Spojine in njihove soli specifične za PPar receptorje in EGF receptorje in njihova uporaba na medicinskem področju
EA201000708A EA017566B1 (ru) 2005-07-22 2006-07-24 Соединения и их соли, специфичные к ppar рецепторам и egf рецепторам, и их применение в области медицины
KR1020087003953A KR101317519B1 (ko) 2005-07-22 2006-07-24 Ppar 수용체 및 egf 수용체에 특이적인 화합물 및이들의 염, 및 의학 분야에서의 이들의 용도
PCT/IE2006/000078 WO2007010516A2 (en) 2005-07-22 2006-07-24 Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field
UAA200802141A UA100359C2 (uk) 2005-07-22 2006-07-24 Сполуки та їхні солі, які є специфічними для ппар-рецепторів та фре-рецепторів, а також їх використання у медичній галузі
NZ566045A NZ566045A (en) 2005-07-22 2006-07-24 Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
MX2013012753A MX366596B (es) 2005-07-22 2006-07-24 Compuestos y sus sales especificas de receptores de ppar y egf y su uso en el campo medico.
BRPI0613396-7A BRPI0613396B1 (pt) 2005-07-22 2006-07-24 Composto, uso do mesmo, e, composição farmacêutica
JP2008522170A JP5312026B2 (ja) 2005-07-22 2006-07-24 Ppar受容体及びegf受容体に特異的な化合物及びそれらの塩並びに医療分野におけるそれらの使用
EP06766085.2A EP1910270B3 (en) 2005-07-22 2006-07-24 Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field
HRP20130549TT HRP20130549T4 (hr) 2005-07-22 2006-07-24 Spojevi i njihove soli specifični za ppar receptore i egf receptore te njihova primjena u području medicine
ES06766085.2T ES2421260T7 (es) 2005-07-22 2006-07-24 Compuestos y sus sales específicos de los receptores PPAR y los receptores del EGF, y su uso en el campo de la medicina
AU2006271165A AU2006271165C1 (en) 2005-07-22 2006-07-24 Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
IL188878A IL188878A (en) 2005-07-22 2008-01-17 Compounds and their special salts for ppar and egf receptors and their use in the medical field
NO20080325A NO340680B1 (no) 2005-07-22 2008-01-18 Forbindelser og deres salter som er spesifikke overfor PPAR-reseptorer og EGF-reseptorer samt deres anvendelse innen medisin
ZA2008/01671A ZA200801671B (en) 2005-07-22 2008-02-20 Compounds and their salts specific to the ppar receptors and the egf recepters and their use in the medical fields
IL205992A IL205992A (en) 2005-07-22 2010-05-26 Compounds and their special salts for ppar and egf receptors and their use in drug preparation
ZA2010/08268A ZA201008268B (en) 2005-07-22 2010-11-18 Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field
US13/408,439 US8710100B2 (en) 2005-07-22 2012-02-29 Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
CY20131100562T CY1114294T1 (el) 2005-07-22 2013-07-05 Ενωσεις και τα αλατα τους που αφορουν τους υποδοχεις ppar και τους υποδοχεις egf kai h χρηση τους στον τομεα της ιατρικης
US14/202,386 US9133099B2 (en) 2005-07-22 2014-03-10 Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
US14/671,579 US9561202B2 (en) 2005-07-22 2015-03-27 Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
US14/671,585 US9345680B2 (en) 2005-07-22 2015-03-27 Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
US15/377,013 US10016381B2 (en) 2005-07-22 2016-12-13 Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000389A ITRM20050389A1 (it) 2005-07-22 2005-07-22 Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.

Publications (1)

Publication Number Publication Date
ITRM20050389A1 true ITRM20050389A1 (it) 2007-01-23

Family

ID=37579831

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000389A ITRM20050389A1 (it) 2005-07-22 2005-07-22 Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.

Country Status (23)

Country Link
US (6) US8153841B2 (enExample)
EP (1) EP1910270B3 (enExample)
JP (1) JP5312026B2 (enExample)
KR (1) KR101317519B1 (enExample)
CN (2) CN102020577B (enExample)
AU (1) AU2006271165C1 (enExample)
CA (1) CA2616146C (enExample)
CY (1) CY1114294T1 (enExample)
DK (1) DK1910270T6 (enExample)
EA (2) EA014665B3 (enExample)
ES (1) ES2421260T7 (enExample)
HR (1) HRP20130549T4 (enExample)
IL (2) IL188878A (enExample)
IT (1) ITRM20050389A1 (enExample)
MX (1) MX366596B (enExample)
NO (1) NO340680B1 (enExample)
NZ (2) NZ566045A (enExample)
PL (1) PL1910270T6 (enExample)
PT (1) PT1910270E (enExample)
SI (1) SI1910270T1 (enExample)
UA (1) UA100359C2 (enExample)
WO (1) WO2007010516A2 (enExample)
ZA (2) ZA200801671B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
IE20070129A1 (en) * 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
ITMI20072429A1 (it) 2007-12-24 2009-06-25 Giuliani Int Ltd Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
UA107562C2 (uk) * 2008-12-05 2015-01-26 Спосіб лікування псоріазу
EA020856B1 (ru) * 2009-02-16 2015-02-27 Джулиани Интернэшнл Лимитед Способы лечения патологических состояний, связанных с волосами
WO2011148956A1 (ja) 2010-05-24 2011-12-01 トーアエイヨー株式会社 縮合イミダゾール誘導体
JP6301844B2 (ja) 2012-02-09 2018-03-28 ノグラ ファーマ リミテッド 線維症の処置方法
EP2844242A1 (en) 2012-04-18 2015-03-11 Nogra Pharma Limited Methods of treating lactose intolerance
FR2996545B1 (fr) 2012-10-08 2016-03-25 Ecole Polytech Procede microfluidique de traitement et d'analyse d'une solution contenant un materiel biologique, et circuit microfluidique correspondant.
JP6496302B2 (ja) * 2014-03-20 2019-04-03 京セラ株式会社 ユーザ端末、通信制御方法及び基地局
WO2017093444A1 (en) * 2015-12-01 2017-06-08 Nogra Pharma Limited Compositions for oral administration in the treatment of inflammatory bowel disease
WO2020152350A1 (en) 2019-01-25 2020-07-30 Nogra Pharma Limited Compositions for use in preventing acne
EP3921299B1 (en) 2019-02-08 2024-11-20 Nogra Pharma Limited Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
WO2025132838A1 (en) 2023-12-20 2025-06-26 Nogra Pharma Limited Acne topical formulations

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB767788A (en) 1953-12-28 1957-02-06 Schering Corp Polyiodinated phenyl fatty acid compounds and process for their manufacture
US3211610A (en) 1961-09-29 1965-10-12 Merck & Co Inc Benzoic acid ester derivatives for treating coccidiosis and method of using same
US3444232A (en) 1966-05-18 1969-05-13 Squibb & Sons Inc O-alkyl or phenylalkyl benzohydroxamic acids
GB1359560A (en) 1972-02-25 1974-07-10 Merck & Co Inc Preparation of pyrrylsalicylic acid
US4036951A (en) 1973-03-12 1977-07-19 Synergistics, Inc. Ultra-violet filtration with certain aminosalicylic acid esters
FR2440353A1 (fr) * 1978-11-03 1980-05-30 Science Union & Cie Nouveaux arylethanols, leurs procedes d'obtention et leur emploi comme medicament
US4348223A (en) * 1980-12-05 1982-09-07 Ppg Industries, Inc. N-Alkyl-N-[3-(alkoxyalkyl)phenyl]-2-haloacetamide herbicides
DE3164618D1 (en) 1980-12-22 1984-08-09 Schering Ag 3-substituted 2,4,6-trihalogenobenzamides and their salts, their preparation and their use as substitutes for natural sweetening agents, and sweeteners containing them
JPS58194814A (ja) 1982-05-11 1983-11-12 Nippon Shinyaku Co Ltd 免疫調節作用を有する薬剤
IL69282A (en) 1982-09-02 1988-06-30 Euro Celtique Sa Method for the carboxylation of potassium phenoxide with carbon dioxide
EP0279096B1 (en) * 1987-02-05 1993-07-07 Kureha Kagaku Kogyo Kabushiki Kaisha Benzyl ether compound and process for producing the same
NZ224087A (en) 1987-04-01 1990-08-28 Dak Lab As Topical pharmaceutical compositions containing 4- or 5- amino salicylic acid or a functional derivative thereof
ES2065980T3 (es) 1988-05-05 1995-03-01 Tillotts Pharma Ag Uso del acido 5-aminosalicilico en el tratamiento de alteraciones dermatologicas.
WO1992006690A1 (en) 1990-10-22 1992-04-30 Borody Thomas J Treatment of non-inflammatory and non-infectious bowel disorders
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
US5262549A (en) 1991-05-30 1993-11-16 Polaroid Corporation Benzpyrylium dyes, and processes for their preparation and use
US5302751A (en) 1992-01-21 1994-04-12 Ethyl Corporation Profen resolution
CA2120367C (en) 1992-06-30 2004-05-11 Howard K. Shapiro Compositions and use of pharmaceutical compositions in the treatment of symptoms of disorders related to chronic inflammatory diseases and etiologically related symptomology
US5594151A (en) 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
EP0759750A4 (en) 1994-05-11 1998-05-27 Howard K Shapiro PREPARATIONS FOR TREATING CHRONIC FLAMMABLE DISEASES
US5594015A (en) 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
HUP9900309A3 (en) 1995-03-28 1999-11-29 Janssen Pharmaceutica Nv Use of ridogrel for producing pharmaceutical compositions for the treatment of inflammatory bowel diseases
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9617001D0 (en) 1996-08-13 1996-09-25 Tillotts Pharma Ag Oral composition
DE19647582A1 (de) 1996-11-18 1998-05-20 Hoechst Ag Verfahren zur Herstellung von aromatischen Olefinen mittels Katalyse durch Palladaphosphacyclobutane
WO1998043081A1 (en) 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Treatment of gastrointestinal disease with ppar modulators
WO1999005161A1 (en) 1997-07-25 1999-02-04 Ligand Pharmaceuticals Incorporated HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA (PPARη) GENE REGULATORY SEQUENCES AND USES THEREFOR
AU9002798A (en) * 1997-09-19 1999-04-12 Ono Pharmaceutical Co. Ltd. Fused or nonfused benzene compounds
FR2773075B1 (fr) 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6114382A (en) 1998-11-11 2000-09-05 Moretti; Itagiba G. Methods for treating inflammatory bowel disease
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
FR2791671B1 (fr) 1999-04-01 2001-05-11 Oreal Nouveaux composes derives d'esters d'acide benzoique, composition les comprenant et utilisation
GB9908647D0 (en) 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
US20040034067A1 (en) 1999-04-15 2004-02-19 Macphee Colin Houston Novel method of treatment
GB9914371D0 (en) 1999-06-18 1999-08-18 Smithkline Beecham Plc Novel compounds
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
DK1274675T3 (da) 2000-04-19 2004-12-06 Neurotech Co Ltd Forbindelser, sammensætninger og fremgangsmåder til forebyggelse af neurodegeneration ved akutte og kroniske skader i centralnervesystemet
AU2001258838A1 (en) * 2000-05-29 2001-12-11 Kyorin Pharmaceutical Co. Ltd. Substituted phenylpropionic acid derivatives
US7049342B2 (en) 2000-05-29 2006-05-23 Kyorin Pharmaceutical Co., Ltd. Substituted phenylpropionic acid derivatives
ATE311358T1 (de) 2000-08-29 2005-12-15 Nobex Corp Immunoregulierende verbindungen, deren derivate und ihre verwendung
WO2002046161A1 (en) 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Substituted carboxylic acid derivatives
FR2822955B1 (fr) 2001-03-27 2003-10-03 Chru Lille Methode de diagnostic de maladies inflammatoires chroniques de l'intestin
CA2443935A1 (en) 2001-04-18 2002-10-31 Merck & Co., Inc. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
CA2354921A1 (en) 2001-05-24 2002-11-24 Yasuo Konishi Drug evolution: drug design at hot spots
US20110105748A1 (en) * 2001-10-16 2011-05-05 Debnath Bhuniya Novel beta-phenyl-alpha-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
US20030113815A1 (en) 2001-12-19 2003-06-19 Pfizer Inc. Canine peroxisome proliferator activated receptor gamma
US20030220374A1 (en) 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20040115127A1 (en) 2002-04-12 2004-06-17 Wright Samuel D. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
US20060159648A1 (en) 2003-02-17 2006-07-20 Davis Adrian F Novel therapeutic method and compositions for topical administration
GB0303609D0 (en) 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
WO2004082715A1 (ja) 2003-03-20 2004-09-30 Eisai Co., Ltd. 炎症性腸疾患治療剤としての併用医薬
ES2337150T3 (es) 2003-07-21 2010-04-21 Merck Serono Sa Alquinilaril carboxamidas.
JP2007509180A (ja) 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ,インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
US20070093476A1 (en) * 2003-10-28 2007-04-26 Bhunia Debnath Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
US20070086967A1 (en) 2003-12-03 2007-04-19 Brian Macdonald Treatment of psoriasis with rosiglitazone
AU2004314731B2 (en) 2004-01-20 2011-07-07 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
WO2005084658A1 (en) 2004-03-04 2005-09-15 Arakis Ltd. Derivatives of actarit and their therapeutic use
US20060286046A1 (en) 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
US20060270635A1 (en) 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
DE102005061472A1 (de) 2005-12-22 2007-07-05 Saltigo Gmbh Verfahren zur Herstellung von enantiomerenangereicherten 2-Alkoxy-3-phenylpropionsäuren
WO2007096148A1 (en) 2006-02-23 2007-08-30 Lipid Nutrition B.V. Immunoregulation
US7645801B2 (en) 2007-01-29 2010-01-12 Alaven Pharmaceutical Llc Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
IE20070129A1 (en) 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
WO2009025854A1 (en) 2007-08-22 2009-02-26 Burnham Institute For Medical Research Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
ITMI20072429A1 (it) 2007-12-24 2009-06-25 Giuliani Int Ltd Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
US8030520B2 (en) 2008-03-31 2011-10-04 Saltigo Gmbh Process for preparing organic compounds by a transition metal-catalysed cross-coupling reaction of an aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halide
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
EA020856B1 (ru) 2009-02-16 2015-02-27 Джулиани Интернэшнл Лимитед Способы лечения патологических состояний, связанных с волосами
EP2298321A1 (en) 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
CA2841358A1 (en) 2011-07-15 2013-01-24 S.L.A. Pharma Ag Pharmaceutical compositions for rectal administration
ES2602075T3 (es) 2011-10-31 2017-02-17 Larsen, Claus Selch Profármacos de agentes antiinflamatorios no esteroideos (AINE)
JP6301844B2 (ja) 2012-02-09 2018-03-28 ノグラ ファーマ リミテッド 線維症の処置方法
EP2844242A1 (en) 2012-04-18 2015-03-11 Nogra Pharma Limited Methods of treating lactose intolerance
BR112014030039A2 (pt) 2012-06-01 2017-06-27 Nogra Pharma Ltd heterociclos bicíclicos capazes de modular respostas de células t e métodos de uso dos mesmos
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
KR20150054934A (ko) 2012-09-13 2015-05-20 노그라 파마 리미티드 모발 관련 상태의 치료 방법
US20150265514A1 (en) 2012-09-13 2015-09-24 Nogra Pharma Limited Methods of inhibiting hair growth
WO2016154730A1 (en) 2015-04-02 2016-10-06 University Health Network Gut anti-inflammatory agents for regulation of high blood glucose levels
KR102722949B1 (ko) 2015-06-15 2024-10-28 엔엠디 파마 에이/에스 신경근 장애의 치료에 사용하기 위한 화합물

Also Published As

Publication number Publication date
MX366596B (es) 2019-07-15
US20150265562A1 (en) 2015-09-24
IL188878A (en) 2013-04-30
PL1910270T6 (pl) 2017-05-31
IL188878A0 (en) 2008-04-13
EP1910270B1 (en) 2013-05-08
NO20080325L (no) 2008-04-16
PL1910270T3 (pl) 2013-09-30
US9133099B2 (en) 2015-09-15
EA014665B1 (ru) 2010-12-30
EA017566B1 (ru) 2013-01-30
US20090048343A1 (en) 2009-02-19
EP1910270A2 (en) 2008-04-16
PT1910270E (pt) 2013-07-17
CN101243039A (zh) 2008-08-13
CA2616146A1 (en) 2007-01-25
ES2421260T7 (es) 2016-10-11
JP2009502777A (ja) 2009-01-29
JP5312026B2 (ja) 2013-10-09
ES2421260T3 (es) 2013-08-30
US20150045436A1 (en) 2015-02-12
CY1114294T1 (el) 2016-08-31
US20150265563A1 (en) 2015-09-24
US20170312239A1 (en) 2017-11-02
NZ566045A (en) 2012-04-27
BRPI0613396A2 (pt) 2011-01-11
US9561202B2 (en) 2017-02-07
EA201000708A1 (ru) 2010-10-29
US8153841B2 (en) 2012-04-10
US9345680B2 (en) 2016-05-24
CN102020577B (zh) 2013-03-13
DK1910270T3 (da) 2013-07-01
WO2007010516A3 (en) 2007-03-29
HRP20130549T1 (en) 2013-07-31
DK1910270T6 (en) 2016-08-29
KR101317519B1 (ko) 2013-10-15
AU2006271165C1 (en) 2016-11-17
ZA200801671B (en) 2011-02-23
EP1910270B3 (en) 2016-05-11
BRPI0613396A8 (pt) 2017-12-26
SI1910270T1 (sl) 2013-08-30
ZA201008268B (en) 2012-04-25
US8710100B2 (en) 2014-04-29
AU2006271165A1 (en) 2007-01-25
CN102020577A (zh) 2011-04-20
EA014665B3 (ru) 2016-09-30
AU2006271165B2 (en) 2012-01-19
UA100359C2 (uk) 2012-12-25
NZ592228A (en) 2012-10-26
WO2007010516A2 (en) 2007-01-25
US10016381B2 (en) 2018-07-10
KR20080039428A (ko) 2008-05-07
NO340680B1 (no) 2017-05-29
EA200800372A1 (ru) 2008-06-30
HRP20130549T4 (hr) 2016-07-15
CN101243039B (zh) 2013-04-03
US20130005813A1 (en) 2013-01-03
CA2616146C (en) 2015-06-30
IL205992A (en) 2014-05-28

Similar Documents

Publication Publication Date Title
ZA201008268B (en) Compounds and their salts specific to the ppar receptors and the egf receptors and their use in the medical field
SMT201500206B (it) Composti spiro-ossindolici e loro uso come agenti terapeutici
EP2130875A4 (en) CYANINE CONNECTION, OPTICAL FILTER WITH CONNECTION AND OPTICAL RECORDING MATERIAL
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
EP2209420A4 (en) PARTICULARS FOR IMAGING
EP2123158A4 (en) HERBICIDE COMPOSITION
EP1891595A4 (en) US CREATED SOCIAL NETWORKS
EP1918681A4 (en) PROTRACTOR
BRPI0817542A2 (pt) NOVOS INIBIDORES DE sEH E SEU USO
IL235943A0 (en) Genistein salts, crystalline forms of same, compositions comprising same and uses thereof
ITRM20050390A1 (it) Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
BRPI0813587A2 (pt) Composto, uso do mesmo, e, composição farmacêutica
BRPI0807377A2 (pt) Uso de rosiglitazona, 5-asa ou compostos, métodos para identificar agentes antiinflamatórios e/ou antimicrobianos, e para identificar agentes antiinflamatórios e antibacterianos potenciais, e, composição
EP2188781A4 (en) IMAGE RECONSTRUCTION
FR2884826B1 (fr) Composition de polissage et procede de polissage l'utilisant
ITPN20050014A1 (it) "piedino livellatore perfezionato"
ITTO20060614A1 (it) "diagnosi differenziale per la sclerodermia"
BRPI0924525A2 (pt) "derivativos de colestanol para uso combinado"
FR2902340B1 (fr) Composition cosmetique a usage topique comprenant du wasabi
BRPI0612406A2 (pt) sal de estrôncio, e, uso do mesmo
EP1990733A4 (en) ERROR DETECTOR
BRPI0819055A2 (pt) "uso de 3-(2,2,2-trimetilhidrazina) propionato e seus sais"
EP2405275A4 (en) STABILIZER FOR MANAGEMENT TEST, MANAGEMENT TEST WITH STABILITY AND MEASUREMENT KIT WITH MANAGEMENT TEST
ITMI20051695A1 (it) Uso di 17a-esteri c3-c10 del 9,11-deidrocortexolone cme agenti anti-gonadotropinici
BRPI0822068A2 (pt) Derivado de 17-(-1'-propenil)-17-3'-oxidoestra-4-en-3-ona, seu uso e o medicamento contendo o derivado